Oruka Therapeutics (ORKA) Assets Average (2011 - 2026)

Oruka Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $496.5 million for Q1 2026.

• On a quarterly basis, Assets Average rose 28.45% year-over-year to $496.5 million in Q1 2026; TTM through Mar 2026 was $496.5 million, a 28.45% increase from a year earlier, with the FY2025 full-year figure at $442.3 million, up 103.89% from the prior year.
• Assets Average held at $496.5 million in Q1 2026 per ORKA's latest filing, from $498.9 million in the prior quarter.
• Across five years, Assets Average topped out at $498.9 million in Q4 2025 and bottomed at $35.3 million in Q2 2024.
• The 5-year median for Assets Average is $49.6 million (2022), against an average of $190.6 million.
• Across the five-year window, Assets Average declined 26.32% in 2022 and soared 951.48% in 2024, its largest moves.
• Year by year, Assets Average stood at $44.0 million in 2022, then dropped by 12.5% to $38.5 million in 2023, then surged by 951.48% to $405.1 million in 2024, then increased by 23.18% to $498.9 million in 2025, then slipped by 0.48% to $496.5 million in 2026.
• Per Business Quant, the three latest ORKA Assets Average figures stand at $496.5 million (Q1 2026), $498.9 million (Q4 2025), and $433.3 million (Q3 2025).